2/20/2023 0 Comments Dex online chicago![]() Results: Of 202 pts (HORIZON: n = 157, cutoff JanuO-12-M1: n = 45, cutoff October 29, 2019), 178 (88%) had been exposed to alkylators in ≥ 1 prior LoT (see Table for subgroups). Refractoriness to prior alkylator therapy was defined as disease that failed to achieve a minimal response or progressed while on therapy, or within 60 d of last therapy. Data from the 2 studies were pooled and analyzed according to previous exposure and refractoriness to alkylators before study entry. Secondary endpoints included progression-free survival (PFS) and safety. Methods: Both the O-12-M1 and HORIZON studies included pts with RRMM who received ≥ 2 prior lines of therapy (LoTs) and had a primary endpoint of overall response rate (ORR). This pooled analysis examines pts from these studies exposed to prior alkylators. In the O-12-M1 (NCT01897714) and HORIZON (OP-106 NCT02963493) studies, melflufen plus dex showed meaningful efficacy and a clinically manageable safety profile in pts with RRMM (Richardson et al. Melflufen has a mechanism of action distinct from other alkylating agents (Slipicevic et al. ![]() Sammons Cancer Center, Dallas, TX The Oncology Institute of Hope and Innovation, Glendale, CA Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA Oncopeptides AB, Stockholm, Swedenīackground: Melphalan flufenamide (melflufen) is a first-in-class peptide-drug conjugate (PDC) that leverages aminopeptidases and rapidly releases alkylating agents inside tumor cells. Clinica Universidad De Navarra, Pamplona, Spain Hospital Clínico Universitario de Salamanca/IBSAL/CIC, Salamanca, Spain Institut Català d’Oncologia and Josep Carreras Research Institute, Hospital Germans Trias i Pujol, Badalona, Spain Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza, Torino, Italy Hematology Department, IDIBAPS, Hospital Clinic, Barcelona, Spain Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy CHU de Poitiers, Poitiers, France Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA Division of Hematology-Oncology, Department of Medicine, University of Florida, Gainesville, FL Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer, New York, NY University Hospital, Nantes, France CRCINA, INSERM, Centre National de la Recherche Scientifique, University of Angers, University of Nantes, Nantes, France Hospital Universitario La Princesa and Hospital Universitario Quironsalud, Madrid, Spain Rush University Medical Center, Chicago, IL Baylor Scott & White Charles A. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |